Targeting galectin-3 in inflammatory and fibrotic diseases
Trends in Pharmacological Sciences, ISSN: 0165-6147, Vol: 44, Issue: 8, Page: 519-531
2023
- 46Citations
- 70Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations46
- Citation Indexes46
- 46
- CrossRef15
- Captures70
- Readers70
- 70
Review Description
Galectin (Gal)-3 is a β-galactoside-binding lectin emerging as a key player in cardiac, hepatic, renal, and pulmonary fibrosis and inflammation, respiratory infections caused by COVID-19, and neuroinflammatory disorders. Here, we review recent information highlighting Gal-3 as a relevant therapeutic target in these specific disease conditions. While a causal link was difficult to establish until now, we discuss how recent strategic breakthroughs allowed us to identify new-generation Gal-3 inhibitors with improved potency, selectivity, and bioavailability, and report their usefulness as valuable tools for proof-of-concept studies in various preclinical models of the aforementioned diseases, with emphasis on those actually in clinical stages. We also address critical views and suggestions intended to expand the therapeutic opportunities provided by this complex target.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0165614723001268; http://dx.doi.org/10.1016/j.tips.2023.06.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85164083520&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37391294; https://linkinghub.elsevier.com/retrieve/pii/S0165614723001268; https://dx.doi.org/10.1016/j.tips.2023.06.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know